The Company is a Korea-based company principally engaged in manufacturing and distributing pharmaceutical products The Company operates its business through two segments: raw material medicine segment, which produces atorvastatin, ceftizoxime, ceftriaxone, clarithromycin and Pranlukast, and medicine segment, which produces surgeon respiratory solution, cefaclor capsule and cefaclor dry syrup. The Company distributes its products within domestic market and to overseas markets including China Japan and Europe. The Company was founded on March 31, 1987. and its shares are listed on Korea Stock Exchange on June 29, 2015.
Headquarters
174 Sirok-Ro
Asan; Chungcheongnam;
Postal Code: 31501
Contact Details: Purchase the Kyongbo Pharmaceutical Co. Ltd. report to view the information.
Website: http://www.kbpharma.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service